CHCWM – Cancer & Hematology Centers of West Michigan

PH1 INBRX-105 (InhibRx)

An Open-Label, Multicenter, First-in-Human, Dose Escalation Phase I study of INBRX-105 in subjects with locally advanced or metastatic solid tumors, Hodgkin or Non-Hodgkin Lymphoma. Mechanism of Action: IgG1 antibody that targets PD-L1 and costimulatory receptor.

Target Patient Population: All solid tumors and lymphomas

Study Design: Drug is given by IV every 3 weeks

Principal Investigator: Dr. Nehal Lakhani